ARCH Venture Partners XII, L.P. has an estimated net worth of $47.2 Million. This is based on reported shares across multiple companies, which include Neumora Therapeutics, Inc., Rapport Therapeutics, Inc., Metsera, Inc., Seaport Therapeutics, Inc., and Prime Medicine, Inc..

2023 was ARCH Venture Partners XII, L.P.'s most active year for acquiring shares with 26 total transactions. ARCH Venture Partners XII, L.P.'s most active month to acquire stocks was the month of August. 2025 was ARCH Venture Partners XII, L.P.'s most active year for disposing of shares, totalling 7 transactions. ARCH Venture Partners XII, L.P.'s most active month to dispose stocks was the month of January. 2025 saw ARCH Venture Partners XII, L.P. paying a total of $54,999,963.00 for 30,698,853 shares, this is the most they've acquired in one year. In 2024 ARCH Venture Partners XII, L.P. cashed out on 31,924,138 shares for a total of $0.00, their largest year based on trade value.